Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine during Ixekizumab treatment for hidradenitis suppurativa.

Iannone, Michela; Janowska, Agata; Tonini, Giulia; Davini, Giulia; Dini, Valentina

Iannone, Michela; Janowska, Agata; Tonini, Giulia; Davini, Giulia; Dini, Valentina.

Afiliación

Iannone M; Department of Dermatology, University of Pisa, Pisa, Italy. Electronic address: drmichelaiannone@gmail.com.
Janowska A; Department of Dermatology, University of Pisa, Pisa, Italy.
Tonini G; Department of Dermatology, University of Pisa, Pisa, Italy.
Davini G; Department of Dermatology, University of Pisa, Pisa, Italy.
Dini V; Department of Dermatology, University of Pisa, Pisa, Italy.

Clin Dermatol ; 39(4): 701-702, 2021.

Article en En | MEDLINE | ID: mdl-34809775

Asunto(s)

COVID-19; Hidradenitis Supurativa; Anticuerpos Monoclonales Humanizados; Vacunas contra la COVID-19; Hidradenitis Supurativa/tratamiento farmacológico; Humanos; ARN Mensajero; SARS-CoV-2

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Hidradenitis Supurativa / COVID-19 Límite: Humans Idioma: En Revista: Clin Dermatol Año: 2021 Tipo del documento: Article Pais de publicación: Estados Unidos

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google